How cholesterol metabolism and transport present novel targets for lipid treatment

John M. Dietschy

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The National Cholesterol Education Program treatment guidelines cite reduction of low-density lipoprotein (LDL) cholesterol as the primary therapeutic focus of lipid-modifying treatment. Statin drugs are the most effective agents for reducing LDL. However, the limited efficacy of currently available agents at low doses suggests a need for alternative therapeutic strategies. Serum cholesterol levels reflect a complicated process of synthesis and transport that affords opportunities for intervention at multiple steps in the process. Combination therapy might improve upon lipid-modifying results that can currently be achieved with statin-based therapy, but tolerability issues related to some of the currently available drugs limit their use. Evolving, new classes of lipid-modifying therapies might improve current capabilities to reduce coronary risk. An ideal therapeutic strategy would target cholesterol absorption, excretion, and synthesis. The development of selective cholesterol absorption inhibitors represents a particularly promising approach to enhancement of LDL reduction by means of combination therapy.

Original languageEnglish (US)
Pages (from-to)S319-S323
JournalAdvanced Studies in Medicine
Issue number4 C
StatePublished - Apr 1 2003

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'How cholesterol metabolism and transport present novel targets for lipid treatment'. Together they form a unique fingerprint.

Cite this